Competitive landscape
Drugs aimed at the same indication, from approved to preclinical.
2 drugs for “NASH - Nonalcoholic Steatohepatitis”
Phase 3 2
- EfruxiferminAkero Therapeutics, Inc.NASH - Nonalcoholic Steatohepatitis
- MGL-3196MADRIGAL PHARMACEUTICALS, INC.NASH - Nonalcoholic Steatohepatitis
Drugs whose recorded indications name this term, by development stage. Indications come from registries and labels, so a drug can appear under related terms.